Iovance Biotherapeutics (IOVA) revenue and earnings history
Iovance Biotherapeutics reported revenue of $264M for fiscal 2025 (year ended Dec 31, 2025), +60.6% on the year before, and net income of −$391M.
Revenue and net income, 18 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $264M+60.6% | −$403M | −$391M | −$302M | $33.8M | −$336M | $61.6M | — | — | $163M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Iovance Biotherapeutics (IOVA) on OQRO.
Common questions
What was Iovance Biotherapeutics's revenue in fiscal 2025?
$264M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 24, 2026. That is +60.6% on fiscal 2024 ($164M).
Has Iovance Biotherapeutics been profitable?
It reported a net loss in 18 of the years shown (2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$16K in fiscal 2009.
What was Iovance Biotherapeutics's free cash flow in fiscal 2025?
Where these figures come from
The SEC’s companyfacts data: every figure Iovance Biotherapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
